{
    "clinical_study": {
        "@rank": "97447", 
        "arm_group": [
            {
                "arm_group_label": "A: systemic chemotherapy LV5FU2 alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab 5 mg/kg over 30 min (according its previous use) every 2 weeks"
            }, 
            {
                "arm_group_label": "B:SIR-spheres+systemic chemotherapy LV5FU2", 
                "arm_group_type": "Active Comparator", 
                "description": "ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab according its previous use (refer to protocol)."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators propose to conduct a randomised phase III trial evaluating a maintenance\n      strategy comparing hepatic arterial injection of Yttrium-90 resin microspheres plus\n      continuing simplified chemotherapy with/without bevacizumab versus continuing simplified\n      chemotherapy with/without bevacizumab alone for patient with dominant or exclusive and\n      unresectable liver mCRC controlled after 3 months of chemotherapy induction."
        }, 
        "brief_title": "Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The aim of the study is to investigate whether an intensified maintenance treatment of SIRT\n      + simplified maintenance chemotherapy has a benefit in terms of time to progression (TTP)\n      compared to simplified chemotherapy maintenance alone, in patients with stable disease after\n      3 months induction therapy. We would like to demonstrate the feasibility and safety of this\n      approach and to investigate if this strategy has the potential to increase the outcome of\n      the patient.\n\n      Primary end-point:\n\n      - Time to first progression (TTP1 overall)\n\n      Secondary end-points:\n\n        -  Time to global progression (TTP1 + TTP2), Time to second progression (TTP2), TTP1 liver\n           only\n\n        -  Progression Free Survival (PFS)\n\n        -  Safety\n\n        -  Ro resection rate\n\n        -  Quality of Life\n\n      Exploratory analysis:\n\n      - Prediction and evaluation of SIR-spheres treatment response (only for Belgian centres)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Willing and able to provide written informed consent\n\n          2. Histologically confirmed adenocarcinoma of the colon or rectum, with or without\n             primary tumour in situ. Unequivocal and measurable (RECIST 1.1) CT evidence of liver\n             metastases which are not treatable by surgical resection and/or local ablation with\n             curative intent at the time of trial entry.\n\n          3. Partial response or stable disease (RECIST 1.1 criteria, controlled metastatic\n             disease) after chemotherapy induction with oxaliplatin or irinotecan- based induction\n             chemotherapy (FOLFOX, FOLFIRI or XELOX) +/- bevacizumab during 3 months.\n\n          4. Trial inclusion must be performed in the 4 months since the date of the first course\n             of chemotherapy (induction) administration.\n\n          5. Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted.\n             Metastases in the lung must either be not more than five nodules in number with no\n             individual nodule more than 1 cm in diameter or 1 single lesion of up to 1.7 cm in\n             diameter. Involvement of lymph nodes in 1 single anatomic region (pelvis, abdomen or\n             chest) are permitted provided their longest diameter measures less than 2 cm.\n\n          6. All imaging evidence used as part of the screening process must be within 28 days\n             prior to the time of randomisation.\n\n          7. Suitable for either treatment regimen as determined by clinical assessment undertaken\n             by the Investigator.\n\n          8. Patients may have received adjuvant chemotherapy or (neo-) adjuvant\n             chemo-radiotherapy to the pelvis, provided the last dose of chemotherapy was\n             administered at least 6 months prior to begin chemotherapy induction. Previous\n             radiotherapy to the pelvis is not an exclusion criterion.\n\n          9. WHO performance status 0 - 1\n\n         10. Adequate haematological, renal and hepatic function as follows:\n\n             Haematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L Renal  Creatinine <\n             1.5 x ULN (Upper Limit Normal) Hepatic         Bilirubin \u2264 1.0 X ULN Albumin\n             \u2265 30g/L ALT             \u2264 5.0 x ULN AST             \u2264 5.0 x ULN LDH             \u2264 2.5\n             x ULN The date of blood tests must be within 28 days prior to the time of\n             randomisation.\n\n         11. Age 18 years or older.\n\n         12. Female patients must either be postmenopausal, sterile (surgically or radiation- or\n             chemically-induced), or if sexually active using an acceptable method of\n             contraception.\n\n         13. Male patients must be surgically sterile or if sexually active and having a\n             pre-menopausal partner must be using an acceptable method of contraception.\n\n         14. Life expectancy of at least 3 months without any active treatment.\n\n         15. Minimum and maximum administered cycles of induction chemotherapy before trial\n             inclusion (date of signed informed consent) should be:\n\n             (i) Xelox: 3-5 cycles (ii) Folfox/Folfiri: 4-7 cycles\n\n        Exclusion criteria\n\n          1. Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour\n             involvement or thrombosis as determined by clinical or radiological assessment.\n\n          2. More than 6 months since last chemotherapy administration before trial inclusion.\n\n          3. Previous radiotherapy delivered to the upper abdomen.\n\n          4. Non-malignant disease that would render the patient unsuitable for treatment\n             according to this protocol.\n\n          5. Prior major liver resection: remnant liver < 50% of the initial liver volume. Patient\n             with a biliary stent can be included.\n\n          6. Liver tumor involvement > 80% before study inclusion (not at diagnosis but when trial\n             inclusion for the patient is planned).\n\n          7. Resectable metastatic disease at trial inclusion.\n\n          8. Progressive disease during first-line metastatic chemotherapy. Adjuvant chemotherapy\n             for colorectal cancer is not an exclusion criterion provided that it was completed\n             more than 6 months prior to start of 1st line therapy.\n\n          9. Utilization of cetuximab or panitumumab during the chemotherapy induction period.\n\n         10. Concomitant utilization of oxaliplatin and irinotecan during chemotherapy induction\n             period (FOLFOXIRI regimen).\n\n         11. Contraindication to further reintroduce oxaliplatin (allergy, permanent grade 2/3\n             neurotoxicity,\u2026).\n\n         12. Pregnant or breast feeding.\n\n         13. Concurrent or prior history of cancer other than adequately treated non-melanoma skin\n             cancer or carcinoma in situ of the cervix.\n\n         14. Allergy to non-ionic contrast agents.\n\n         15. The period between day 1 of the first induction chemo cycle after disease diagnosis\n             and inclusion (date of signed informed consent) must not exceed 4 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895257", 
            "org_study_id": "The SIR-step trial", 
            "secondary_id": "2012-000508-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "B:SIR-spheres+systemic chemotherapy LV5FU2", 
                "description": "Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.\nHepatic Angiogram\nLiver-Lung Break-Through Nuclear Scan", 
                "intervention_name": "HAI-90Y radioembolization (SIR-spheres injection)", 
                "intervention_type": "Device", 
                "other_name": [
                    "Sir-spheres microspheres", 
                    "SIRT"
                ]
            }, 
            {
                "arm_group_label": "A: systemic chemotherapy LV5FU2 alone", 
                "description": "Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.\nCycle 1 onwards:\nDay 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m\u00b2) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.", 
                "intervention_name": "systemic chemotherapy LV5FU2", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Leucovorin L", 
                    "Levoleucovorin", 
                    "5-FU", 
                    "5-Fluoro-Uracil"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TTP1", 
            "TTP2", 
            "PFS", 
            "Safety", 
            "R0 resection rate", 
            "Quality of life"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2650"
                    }, 
                    "name": "University of Antwerp"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }, 
                    "name": "ASZ Aalst"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "CUB H\u00f4pital Erasme"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "investigator": {
                    "last_name": "Am\u00e9lie Deleporte, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "University of St-Luc"
                }, 
                "investigator": {
                    "last_name": "Marc Van den Eynde", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Grand H\u00f4pital de Charleroi"
                }, 
                "investigator": {
                    "last_name": "Javier Carrasco, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "CHU de Li\u00e8ge"
                }, 
                "investigator": {
                    "last_name": "Marc Polus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Cancer Which Are Controlled After Induction Systemic Therapy", 
        "other_outcome": {
            "description": "Prediction and evaluation of SIRspheres treatment response (only for Belgian sites)", 
            "measure": "SIR-spheres treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 42 months"
        }, 
        "overall_contact": {
            "email": "nath.verbist@bgdo.org", 
            "last_name": "Nathalie Verbist", 
            "phone": "+32474074584"
        }, 
        "overall_contact_backup": {
            "email": "iris.verhaegen@uza.be", 
            "last_name": "Iris Verhaegen", 
            "phone": "+32(0)8215681"
        }, 
        "overall_official": [
            {
                "affiliation": "Universiteit Antwerpen", 
                "last_name": "Marc Peters", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of St-Luc", 
                "last_name": "Marc Van den Eynde", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to first progression (TTP1 overall)", 
            "measure": "Time to progression (TTP1 overall)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895257"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universiteit Antwerpen", 
            "investigator_full_name": "Prof. Marc Peeters", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "- Time to global progression (TTP1 + TTP2), Time to second progression (TTP2), TTP1 liver only", 
                "measure": "Time to global progression (TTP1 + TTP2)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 months"
            }, 
            {
                "description": "Progression free survival", 
                "measure": "PFS", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 months"
            }, 
            {
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 months"
            }, 
            {
                "measure": "R0 resection rate", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 months"
            }, 
            {
                "description": "Using\nEORTC QLQ C30\nEQ-5D", 
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 months"
            }
        ], 
        "source": "Universiteit Antwerpen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universiteit Antwerpen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}